Metraipolis › archive › dc_c9da003bebfd

Structure and function of therapeutic antibodies approved by the US FDA in 2025 — Europe PMC PMID:42729864

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42729864
DOI
10.1093/abt/tbag027
License (as archived)
solo-consultazione
Archived
2026-11-01T03:27:48.267Z
SHA-256 of the archived text
84d74bdc0e3c0689fb364d55a07dd75de611e31b8f86201555de33e97f28c12e
Stable URL of this page
https://metraipolis.com/documento/dc_c9da003bebfd

How to cite

Structure and function of therapeutic antibodies approved by the US FDA in 2025 — Europe PMC PMID:42729864 — Europe PMC (en), https://europepmc.org/article/MED/42729864 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c9da003bebfd (Metraipolis archive dc_c9da003bebfd, sha256 84d74bdc0e3c0689fb364d55a07dd75de611e31b8f86201555de33e97f28c12e)
BibTeX
@misc{dcc9da003bebfd,
  title = {Structure and function of therapeutic antibodies approved by the US FDA in 2025 — Europe PMC PMID:42729864},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42729864},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c9da003bebfd; sha256 84d74bdc0e3c0689fb364d55a07dd75de611e31b8f86201555de33e97f28c12e},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42729864. Agents can read the archived copy with the MCP tool read_document.